meso-Thiophenium Porphyrins and Their Zn(II) Complexes: A New Category of Cationic Photosensitizers.

Abstract:

:A new category of cationic meso-thiophenium porphyrins are introduced as possible alternatives to the popular meso-pyridinium porphyrins. Combinations of cationic porphyrins bearing meso-2-methylthiophenium and meso-4-hydroxyphenyl moieties T2(OH)2M (A2B2 type) and T(OH)3M (AB3 type) along with their zinc(II) complexes T2(OH)2MZn and T(OH)3MZn, are reported. The increase in the number of thienyl groups attached to the meso-positions of the porphyrin derivatives (A2B2 frame) has been shown to impart longer fluorescence lifetimes and stronger photocytotoxicity toward A549 lung cancer cells, as evident with T2(OH)2M and its corresponding diamagnetic metal complex T2(OH)2MZn. The photoactivated T2(OH)2MZn imparts an early stage reactive oxygen species (ROS) upregulation and antioxidant depletion in A549 cells and contributes to the strongest oxidative stress-induced cell death mechanism in the series. The DFT calculations of the singlet-triplet energy gap (ΔE) of all the four hydrophilic thiophenium porphyrin derivatives establish the potential applicability of these cationic photosensitizers as PDT agents.

journal_name

ACS Med Chem Lett

authors

Mazumdar ZH,Sharma D,Mukherjee A,Basu S,Shukla PK,Jha T,Sengupta D

doi

10.1021/acsmedchemlett.0c00266

subject

Has Abstract

pub_date

2020-09-10 00:00:00

pages

2041-2047

issue

10

issn

1948-5875

journal_volume

11

pub_type

杂志文章
  • Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

    abstract::Inhibition of the lipid kinase PI3Kδ is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3Kδ isoform selective analogues with good pharmacokinetic properties. With compo...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00119

    authors: Hoegenauer K,Soldermann N,Stauffer F,Furet P,Graveleau N,Smith AB,Hebach C,Hollingworth GJ,Lewis I,Gutmann S,Rummel G,Knapp M,Wolf RM,Blanz J,Feifel R,Burkhart C,Zécri F

    更新日期:2016-06-02 00:00:00

  • Diphenylpyrazoles as replication protein a inhibitors.

    abstract::Replication Protein A is the primary eukaryotic ssDNA binding protein that has a central role in initiating the cellular response to DNA damage. RPA recruits multiple proteins to sites of DNA damage via the N-terminal domain of the 70 kDa subunit (RPA70N). Here we describe the optimization of a diphenylpyrazole carbox...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml5003629

    authors: Waterson AG,Kennedy JP,Patrone JD,Pelz NF,Feldkamp MD,Frank AO,Vangamudi B,Souza-Fagundes EM,Rossanese OW,Chazin WJ,Fesik SW

    更新日期:2014-11-11 00:00:00

  • Spotlight on fluorescent biosensors-tools for diagnostics and drug discovery.

    abstract::Fluorescent biosensors constitute potent tools for probing biomolecules in their natural environment and for visualizing dynamic processes in complex biological samples, living cells, and organisms. They are well suited for highlighting molecular alterations associated with pathological disorders, thereby offering mea...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400472e

    authors: Morris MC

    更新日期:2013-12-18 00:00:00

  • Design of Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

    abstract::Multitarget anti-inflammatory drugs interfering with the arachidonic acid cascade exhibit superior efficacy. In this study, a prototype dual inhibitor of soluble epoxide hydrolase (sEH) and LTA4 hydrolase (LTA4H) with submicromolar activity toward both targets has been designed and synthesized. Preliminary structure-a...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00330

    authors: Hiesinger K,Schott A,Kramer JS,Blöcher R,Witt F,Wittmann SK,Steinhilber D,Pogoryelov D,Gerstmeier J,Werz O,Proschak E

    更新日期:2019-10-30 00:00:00

  • Discovery of a potent thiadiazole class of histamine h3 receptor antagonist for the treatment of diabetes.

    abstract::A series of novel 2-piperidinopiperidine thiadiazoles were synthesized and evaluated as new leads of histamine H3 receptor antagonists. The 4-(5-([1,4'-bipiperidin]-1'-yl)-1,3,4-thiadiazol-2-yl)-2-(pyridin-2-yl)morpholine (5u) displayed excellent potency and ex vivo receptor occupancy. Compound 5u was also evaluated i...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml200250t

    authors: Rao AU,Shao N,Aslanian RG,Chan TY,Degrado SJ,Wang L,McKittrick B,Senior M,West RE Jr,Williams SM,Wu RL,Hwa J,Patel B,Zheng S,Sondey C,Palani A

    更新日期:2011-11-21 00:00:00

  • Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.

    abstract::Inhibition of Itk potentially constitutes a novel, nonsteroidal treatment for asthma and other T-cell mediated diseases. In-house kinase cross-screening resulted in the identification of an aminopyrazole-based series of Itk inhibitors. Initial work on this series highlighted selectivity issues with several other kinas...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400206q

    authors: Alder CM,Ambler M,Campbell AJ,Champigny AC,Deakin AM,Harling JD,Harris CA,Longstaff T,Lynn S,Maxwell AC,Mooney CJ,Scullion C,Singh OM,Smith IE,Somers DO,Tame CJ,Wayne G,Wilson C,Woolven JM

    更新日期:2013-08-12 00:00:00

  • EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity.

    abstract::Inhibitors of the protein methyltransferase Enhancer of Zeste Homolog 2 (EZH2) may have significant therapeutic potential for the treatment of B cell lymphomas and other cancer indications. The ability of the scientific community to explore fully the spectrum of EZH2-associated pathobiology has been hampered by the la...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.5b00037

    authors: Campbell JE,Kuntz KW,Knutson SK,Warholic NM,Keilhack H,Wigle TJ,Raimondi A,Klaus CR,Rioux N,Yokoi A,Kawano S,Minoshima Y,Choi HW,Porter Scott M,Waters NJ,Smith JJ,Chesworth R,Moyer MP,Copeland RA

    更新日期:2015-03-04 00:00:00

  • Correction to "Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease".

    abstract::[This corrects the article DOI: 10.1021/acsmedchemlett.8b00507.]. ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 已发布勘误

    doi:10.1021/acsmedchemlett.9b00316

    authors: De Simone A,La Pietra V,Betari N,Petragnani N,Conte M,Daniele S,Pietrobono D,Martini C,Petralla S,Casadei R,Davani L,Frabetti F,Russomanno P,Novellino E,Montanari S,Tumiatti V,Ballerini P,Sarno F,Nebbioso A,Altucci

    更新日期:2019-08-06 00:00:00

  • Novel Benzofurans with (99m)Tc Complexes as Probes for Imaging Cerebral β-Amyloid Plaques.

    abstract::Two novel benzofuran derivatives coupled with (99m)Tc complexes were tested as probes for imaging cerebral β-amyloid plaques using single photon emission tomography. Although both derivatives bound to Aβ(1-42) aggregates, (99m)Tc-BAT-BF showed higher affinity than (99m)Tc-MAMA-BF. In sections of brain tissue from an a...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml100140d

    authors: Ono M,Fuchi Y,Fuchigami T,Kobashi N,Kimura H,Haratake M,Saji H,Nakayama M

    更新日期:2010-08-02 00:00:00

  • Structural Approach to Assessing the Innovativeness of New Drugs Finds Accelerating Rate of Innovation.

    abstract::Measuring innovation in the pharmaceutical industry is challenging. Counts of new molecular entities (NMEs) approved by the Food and Drug Administration (FDA) are commonly used, but this measure only gauges quantity not innovativeness. A new indicator of innovation for small molecule and peptide drugs based on structu...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00319

    authors: Wills TJ,Lipkus AH

    更新日期:2020-09-10 00:00:00

  • Novel Type of Prodrug Activation through a Long-Range O,N-Acyl Transfer: A Case of Water-Soluble CREB Inhibitor.

    abstract::CREB (cAMP response element binding protein) has been shown to play an important role in tumor initiation, progression, and metastasis. We discovered that naphthol AS-E, a cell-permeable CREB inhibitor, presented antiproliferative activity in a broad panel of cancer cell lines in vitro. However, it has limited aqueous...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500330n

    authors: Li BX,Xie F,Fan Q,Barnhart KM,Moore CE,Rheingold AL,Xiao X

    更新日期:2014-08-22 00:00:00

  • Structure-Activity Relationship Studies of 3- or 4-Pyridine Derivatives of DS-6930.

    abstract::Derivatization efforts were continued to discover backups for a potent selective PPARγ modulator, DS-6930. In this Letter, the replacement of 2-pyridine ring in DS-6930 with 3- or 4-pyridyl group is reported. As the introduction of substituents on the pyridine ring did not provide potent partial agonists, modification...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00645

    authors: Shinozuka T,Tsukada T,Fujii K,Tokumaru E,Matsui Y,Wakimoto S,Ogata T,Araki K,Sawamura R,Watanabe N,Mori M,Tanaka J

    更新日期:2019-02-26 00:00:00

  • Discovery of a Novel Selective Dual Peroxisome Proliferator-Activated Receptor α/δ Agonist for the Treatment of Primary Biliary Cirrhosis.

    abstract::A novel peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist 5c was developed with an EC50 of 8 nM for PPARα, 5 nM for PPARδ, and >300-fold selectivity against PPARγ (EC50 = 2939 nM), respectively. Further ADME and pharmacokinetic studies indicated 5c possessed distinguished in vitro and in vivo profiles...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00189

    authors: Jiang Z,Liu X,Yuan Z,He H,Wang J,Zhang X,Gong Z,Hou L,Shen L,Guo F,Zhang J,Wang J,Xu D,Liu Z,Li H,Chen X,Long C,Li J,Chen S

    更新日期:2019-06-24 00:00:00

  • Methyl Scanning and Revised Binding Mode of 2-Pralidoxime, an Antidote for Nerve Agent Poisoning.

    abstract::Organophosphorus nerve agents (OPNAs) inhibit acetylcholinesterase (AChE) and, despite the Chemical Weapons Convention arms control treaty, continue to represent a threat to both military personnel and civilians. 2-Pralidoxime (2-PAM) is currently the only therapeutic countermeasure approved by the United States Food ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00586

    authors: Gambino A,Burnett JC,Koide K

    更新日期:2020-01-09 00:00:00

  • Structure-activity studies of divin: an inhibitor of bacterial cell division.

    abstract::We describe the synthesis and SAR studies of divin-a small molecule that blocks bacterial division by perturbing the assembly of proteins at the site of cell septation. The bacteriostatic mechanism of action of divin is distinct from other reported inhibitors of bacterial cell division and provides an opportunity for ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400234x

    authors: Zhou M,Eun YJ,Guzei IA,Weibel DB

    更新日期:2013-09-12 00:00:00

  • Novel (64)Cu-Labeled CUDC-101 for in Vivo PET Imaging of Histone Deacetylases.

    abstract::We report the design, synthesis, and biological evaluation of a (64)Cu-labeled histone deacetylase (HDAC) imaging probe, which was obtained by introduction of metal chelator through click reaction of HDAC inhibitor CUDC-101 and then radiolabeled with (64)Cu. The resulting (64)Cu-labeled compound 7 ([(64)Cu]7) was iden...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml400191z

    authors: Meng Q,Li F,Jiang S,Li Z

    更新日期:2013-07-25 00:00:00

  • Benzofuran-Based Carboxylic Acids as Carbonic Anhydrase Inhibitors and Antiproliferative Agents against Breast Cancer.

    abstract::Pursuing our effort for developing effective inhibitors of the cancer-related hCA IX isoform, here we describe the synthesis of novel benzofuran-based carboxylic acid derivatives, featuring the benzoic (9a-f) or hippuric (11a,b) acid moieties linked to 2-methylbenzofuran or 5-bromobenzofuran tails via an ureido linker...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00094

    authors: Eldehna WM,Nocentini A,Elsayed ZM,Al-Warhi T,Aljaeed N,Alotaibi OJ,Al-Sanea MM,Abdel-Aziz HA,Supuran CT

    更新日期:2020-03-18 00:00:00

  • A new challenging and promising era of tyrosine kinase inhibitors.

    abstract::Protein kinases are key regulators that govern complex cellular processes. Dysregulation of kinase signaling is associated in many human diseases, particularly cancers and developmental and metabolic disorders. Tyrosine kinase inhibitors have achieved great success in molecular targeted therapies for cancer and now is...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500091p

    authors: Cui JJ

    更新日期:2014-03-06 00:00:00

  • Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors.

    abstract::Potent JNK3 isoform selective inhibitors were developed from a thiophenyl-pyrazolourea scaffold. Through structure activity relationship (SAR) studies utilizing enzymatic and cell-based assays, and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies, potent and highly selective JNK3 inhibitors with...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.0c00533

    authors: Feng Y,Park H,Bauer L,Ryu JC,Yoon SO

    更新日期:2020-12-13 00:00:00

  • Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.

    abstract::We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in v...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml5001239

    authors: Chobanian HR,Guo Y,Liu P,Chioda MD,Fung S,Lanza TJ,Chang L,Bakshi RK,Dellureficio JP,Hong Q,McLaughlin M,Belyk KM,Krska SW,Makarewicz AK,Martel EJ,Leone JF,Frey L,Karanam B,Madeira M,Alvaro R,Shuman J,Salituro G

    更新日期:2014-04-10 00:00:00

  • De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.

    abstract::P-glycoprotein (Pgp) is capable of recognizing and transporting a wide range of chemically diverse compounds in vivo. Overcoming Pgp-mediated efflux can represent a significant challenge when penetration into the central nervous system is required or within the context of developing anticancer therapies. While numerou...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml300314h

    authors: Gunaydin H,Weiss MM,Sun Y

    更新日期:2012-11-06 00:00:00

  • Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.

    abstract::Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the treatment of cancer. Novobiocin was the first natural product identified as an Hsp90 C-terminal inhibitor; however, it manifests poor antiproliferative activity. In contrast to N-terminal inhibitors, novobiocin does not ind...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml5004475

    authors: Garg G,Zhao H,Blagg BS

    更新日期:2014-12-12 00:00:00

  • GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis.

    abstract::GPBAR1 agonists have been identified as potential leads for the treatment of diseases related to colon inflammation such as Crohn's and ulcerative colitis. In this paper, we report the discovery of a small library of hyodeoxycholane analogues, decorated at C-6 with different substituents, as potent and selective GPBAR...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00636

    authors: Marino S,Finamore C,Biagioli M,Carino A,Marchianò S,Roselli R,Giorgio CD,Bordoni M,Di Leva FS,Novellino E,Cassiano C,Limongelli V,Zampella A,Festa C,Fiorucci S

    更新日期:2020-03-02 00:00:00

  • Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-β-lactamase-1.

    abstract::Bacterial resistance has become a worldwide concern after the emergence of metallo-β-lactamases (MBLs). They represent one of the major mechanisms of bacterial resistance against beta-lactam antibiotics. Among MBLs, New Delhi metallo-β-lactamase-1 NDM-1, the most prevalent type, is extremely efficient in inactivating ...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.7b00428

    authors: Spyrakis F,Celenza G,Marcoccia F,Santucci M,Cross S,Bellio P,Cendron L,Perilli M,Tondi D

    更新日期:2017-11-26 00:00:00

  • Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages.

    abstract::Imidazopyridine 1 was identified from a phenotypic screen against P. falciparum (Pf) blood stages and subsequently optimized for activity on liver-stage schizonts of the rodent parasite P. yoelii (Py) as well as hypnozoites of the simian parasite P. cynomolgi (Pc). We applied these various assays to the cell-based lea...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml500244m

    authors: Zou B,Nagle A,Chatterjee AK,Leong SY,Tan LJ,Sim WL,Mishra P,Guntapalli P,Tully DC,Lakshminarayana SB,Lim CS,Tan YC,Abas SN,Bodenreider C,Kuhen KL,Gagaring K,Borboa R,Chang J,Li C,Hollenbeck T,Tuntland T,Zeeman A

    更新日期:2014-07-06 00:00:00

  • Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR.

    abstract::The identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cel...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.8b00002

    authors: Yu T,Li N,Wu C,Guan A,Li Y,Peng Z,He M,Li J,Gong Z,Huang L,Gao B,Hao D,Sun J,Pan Y,Shen L,Chan C,Lu X,Yuan H,Li Y,Li J,Chen S

    更新日期:2018-02-27 00:00:00

  • PAR2 Modulators Derived from GB88.

    abstract::PAR2 antagonists have potential for treating inflammatory, respiratory, gastrointestinal, neurological, and metabolic disorders, but few antagonists are known. Derivatives of GB88 (3) suggest that all four of its components bind at distinct PAR2 sites with the isoxazole, cyclohexylalanine, and isoleucine determining a...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.6b00306

    authors: Yau MK,Liu L,Suen JY,Lim J,Lohman RJ,Jiang Y,Cotterell AJ,Barry GD,Mak JY,Vesey DA,Reid RC,Fairlie DP

    更新日期:2016-10-10 00:00:00

  • Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.

    abstract::Novel 3,3-spiroanellated 5-aryl, 6-arylvinyl-substituted 1,2,4-trioxanes 19-34 have been synthesized and appraised for their antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in Swiss mice by oral route at doses ranging from 96 mg/kg × 4 days to 24 mg/kg × 4 days. The most active compound...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml300188t

    authors: Maurya R,Soni A,Anand D,Ravi M,Raju KS,Taneja I,Naikade NK,Puri SK,Wahajuddin,Kanojiya S,Yadav PP

    更新日期:2012-12-11 00:00:00

  • Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 Diabetes.

    abstract::All eight of the major active metabolites of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221, compound 1), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 that has entered the clinic for the treatment of type 2 diabetes, were synthetically prepared and confirmed...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/ml2001467

    authors: Li A,Yuan CC,Chow D,Chen M,Emery MG,Hale C,Zhang X,Subramanian R,St Jean DJ Jr,Komorowski R,Véniant M,Wang M,Fotsch C

    更新日期:2011-09-13 00:00:00

  • INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).

    abstract::A medicinal chemistry effort focused on identifying a structurally diverse candidate for phosphoinositide 3-kinase delta (PI3Kδ) led to the discovery of clinical candidate INCB050465 (20, parsaclisib). The unique structure of 20 contains a pyrazolopyrimidine hinge-binder in place of a purine motif that is present in o...

    journal_title:ACS medicinal chemistry letters

    pub_type: 杂志文章

    doi:10.1021/acsmedchemlett.9b00334

    authors: Yue EW,Li YL,Douty B,He C,Mei S,Wayland B,Maduskuie T,Falahatpisheh N,Sparks RB,Polam P,Zhu W,Glenn J,Feng H,Zhang K,Li Y,He X,Katiyar K,Covington M,Feldman P,Shin N,Wang KH,Diamond S,Li Y,Koblish HK,Hall

    更新日期:2019-10-17 00:00:00